Salute e Benessere

Health Canada Approves Aktiia Bracelet: First Consumer Blood Pressure Wearable…

How Does Aktiia's Bracelet Work?The precision monitoring device can take readings automatically whether users are awake or asleep, providing up to 800 measurements a month to understand what impacts blood pressure. How Does Aktiia's Bracelet Work?The precision monitoring device can take readings automatically whether users are awake or asleep, providing up to 800 measurements a month to understand what impacts blood pressure. These insights help users understand what impacts blood...
PR Newswire
19/11/2024

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to…

"We are honored to join forces with The Michael J. Fox Foundation, a true leader in driving research toward a cure for Parkinson's disease," said Yuling Luo, Founder, Chairman & CEO of Alamar Biosciences. "The comprehensive analysis of the PPMI cohort using our NULISAseq™ technology provides a unique opportunity to uncover new insights into disease mechanisms and accelerate the development of targeted therapies." "We are honored to join forces with The Michael J. Fox…
PR Newswire
19/11/2024

Meril Champions Innovation with Myval Octapro THV Launch at GISE 2024 & PCR…

The Myval THV series* has a profound impact & has been instrumental in advancing transcatheter aortic valve replacement (TAVR) therapy, making a significant positive impact on patients' lives. Characterized by reduced frame foreshortening leading to higher operator control and predictive deployment; availability of a large size matrix comprising of conventional, intermediate and extra-large valve diameters allowing better bioprosthetic valve sizing for individual patient and supported by a…
PR Newswire
19/11/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
19/11/2024

Boehringer's focus on Health Equity drives significant upgrade in Access to…

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the company's strategic shift of prioritizing Health Equity as its primary contribution to the United Nations Sustainable Development Goals (UN SDGs). Every two years the ATMI evaluates the efforts of the world's leading pharmaceutical companies and ranks the top 20 based on their efforts to...
Nasdaq GlobeNewswire
19/11/2024

Transpara Improves Cancer Detection by Decreasing False Negative Cancers

The false negative cancers detected by Transpara were all invasive and predominantly (82%) luminal A subtype. The luminal A breast cancer is the most common subtype, representing 50–60% of all breast cancers. In the Digital Breast Tomosynthesis (DBT) cohort, all of the interval cancers detected were in dense breasts. As dense breast tissue is often associated both with decreased mammographic sensitivity and increased individual risk, the ability of Transpara to detect these interval cancers…
PR Newswire
19/11/2024

TRACE International Releases the 2024 Bribery Risk Matrix

The updated 2024 matrix reveals substantial movement in scores across countries, with many improvements but also many deteriorations. Some of these changes are driven by the inclusion of new data, while others reflect a shift in components. About 90% of the data sources used to calculate matrix scores have provided an update in 2024, with only one data source, Transparency Index, featuring no updates. Most notably, the most recent World Bank Enterprise (WBES) survey included new economies in its…
PR Newswire
19/11/2024

Novartis ranks first in 2024 Access to Medicine Index

The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industry Novartis has risen three places to secure the top spot on the 2024 Access to Medicine IndexBasel, November 19, 2024–...
Nasdaq GlobeNewswire
19/11/2024

Akari Therapeutics Regains Full Nasdaq Compliance

- Shareholders Equity Deficiency has been Cured -- Akari will Continue to be Listed and Traded on The Nasdaq Stock Market -BOSTON and LONDON, Nov.19, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured. The Company is now in full compliance with all Nasdaq continued listing...
Nasdaq GlobeNewswire
19/11/2024

2024 Access to Medicine Index finds that pharma companies are missing…

Despite the pharmaceutical industry's evident potential to drive expansion of access to medicines, the 2024 Index results show that both product and geographic coverage remain inconsistent, leaving significant portions of the world's poorest populations overlooked and underserved. Despite the pharmaceutical industry's evident potential to drive expansion of access to medicines, the 2024 Index results show that both product and geographic coverage remain inconsistent, leaving significant...
PR Newswire
19/11/2024

TELUS Mental Health Index: Workers who are dissatisfied with their physical…

"There is a clear link between physical activity, employer support and employee wellbeing. At TELUS Health, we've seen that those employees whose physical health and wellbeing is supported by their employer have better mental health and higher productivity - outcomes for which every business owner strives" said Paula Allen, Global Leader, Research & Client Insights, TELUS Health. "This underscores the need for organizations to prioritize wellbeing as a strategic pillar of…
PR Newswire
19/11/2024

TELUS Mental Health: Physically active workers lose 12 fewer workdays of…

"There is a clear link between physical activity, employer support and employee wellbeing. At TELUS Health, we've seen that supported, active employees have better mental health and higher productivity - outcomes for which every business owner strives" said Paula Allen, Global Leader, Research & Client Insights, TELUS Health. "This underscores the need for organizations to prioritize wellbeing as a strategic pillar of business success. By integrating robust support systems…
PR Newswire
19/11/2024

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the…

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its clinical course can be rapid with marked disability even at an early stage. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Few treatment options exist, resulting in a high unmet...
Nasdaq GlobeNewswire
19/11/2024

Digital Medicine Society Launches Resources to Navigate Global Digital Health…

DiMe's resources respond to uncertainty from developers about the requirements for and differences between pathways in Australia, China, England, France, Germany, Japan, South Korea, and the U.S. They include tools like country-specific regulatory guides, step-by-step flowcharts, and AI/ML guidelines that provide DHT developers with clear and actionable pathways to navigate requirements across diverse markets. DiMe's resources respond to uncertainty from developers about the requirements for...
PR Newswire
19/11/2024

Ardena's New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval…

The approval follows a €20 million investment in a state-of-the-art 45,000 sqft facility offering GMP-compliant Grade C and Grade D cleanrooms designed specifically for nanomedicine manufacturing. The fit-for-purpose cleanrooms, alongside additional GMP production spaces, dedicated laboratories for process development and analytical capabilities, and advanced warehouse facilities, reflect Ardena's commitment to meeting stringent regulatory standards, including the latest updates to Annex 1...
Nasdaq GlobeNewswire
19/11/2024

Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker…

Dr Brannan and Dr Baker join a highly accomplished team of CNS experts in the field, including Dr Michael Sand, former Senior Program Leader of CNS Research at Boehringer Ingelheim. Dr Sand's extensive expertise in schizophrenia drug development has already significantly contributed to Monument's approach in developing MT1988. Together, the SAB members will be instrumental in driving Monument's schizophrenia program and broader innovation and commercialisation strategies. Dr Brannan and Dr...
PR Newswire
19/11/2024

Augere Medical secures NOK 23M in the “first close” funding round

The proceeds will be used to strengthen the PolypAID European sales & marketing efforts and to expand the AI development capabilities The AI-driven PolypAID™ system helps clinicians and healthcare providers to augment screening of colorectal cancer. The proceeds will be used to strengthen the European sales and marketing efforts as well as hire highly skilled AI development engineers. In addition, Augere has started regulatory activities towards larger overseas markets and expects to...
Nasdaq GlobeNewswire
19/11/2024

Resolution Therapeutics Announces Approval of Clinical Trial Application by…

EDINBURGH, Scotland and LONDON, Nov. 19, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in inflammatory and fibrotic diseases, today announces it has received approval of a clinical trial application from the Spanish Agency of Medicines and Medical Products (AEMPS) to commence the Phase 1/2 EMERALD Study evaluating its lead candidate RTX001 in Spain. EDINBURGH…
PR Newswire
19/11/2024

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy. The additional Phase 3 trial, SOLAR-STAGE, a multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in staging of men with newly diagnosed unfavorable intermediate-risk, high-risk or very-high-risk prostate cancer electing to undergo radical prostatectomy with pelvic lymph node dissection continues to enroll patients at sites…
Nasdaq GlobeNewswire
19/11/2024

Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic…

Freya is developing microbial immunotherapies to regulate the immune system and inflammatory responses in the vaginal tract using its DYSCOVERTM platform. Freya has identified Lactobacillus strains that are capable of engrafting in the vaginal tract thereby displacing the existing dysbiotic vaginal microbiome and reducing key inflammation biomarkers. To date the platform has yielded Freya's lead candidate, FB301 for improving pregnancy success in IVF. Freya is developing microbial...
PR Newswire
19/11/2024

Norberg Partner Sustainable Group AB has sold its holding in Aino Health AB…

Aino Health has been informed that Norberg Partner Sustainable Group AB has yesterday sold 98 748 884 shares to two Finnish investment companies. Nexit III Ky has purchased 59 249 330 shares and Tenendum Oy 39 499 554 shares. After the transactions, Norberg Partner Sustainable Group AB owns 0 percent of the shares in Aino Health AB, Nexit III Ky 29 percent and Tenendum Oy 19.3 percent. More information about the new ownersNexit Ventures Oy is an experienced Finnish Venture Capital company...
Nasdaq GlobeNewswire
19/11/2024

ZINZINO AB (PUBL.): INTERIM REPORT THIRD QUARTER 2024

Revenues in the third quarter of 2024 amounted to SEK 532.8 (436.9) million, corresponding to 22% (25%) growth compared to the corresponding period last year. In local currencies, revenues increased by 24% compared to the third quarter of the previous year. EBITDA profit amounted to SEK 63.0 (71.2) million and the EBITDA margin was 11.8% (16.3%). The EBITDA margin was compared to a very strong third quarter last year and the change was mainly due to the marginally weaker gross profit for the…
PR Newswire
19/11/2024

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in…

Two separate preclinical studies were conducted in collaboration with Ncardia, a leading human induced pluripotent stem cell (iPSC) technology company. The first study evaluated the ability of NUZ-001 and its major active metabolite (NUZ-001 Sulfone) to reduce TDP-43 aggregation in M337V Motor Neurons co-cultured with astrocytes in response to a stressor. TAR DNA-binding protein 43 (TDP-43) is a known driver of ALS pathology. The results show NUZ-001 and NUZ-001 Sulfone significantly and…
PR Newswire
19/11/2024

Essity expands its athletics tape production in France

The new fully automated production line is located at Essity's site in Vibraye, France and will fivefold the production capacity of Leukotape K. The investment amounted to EUR 1m. The new fully automated production line is located at Essity's site in Vibraye,Franceand will fivefold the production capacity of Leukotape K. The investment amounted to EUR 1m. "We are proud to announce that we are expanding the production at our Vibraye site, dedicated to producing high-quality medical...
PR Newswire
19/11/2024
Altri  Comunicati